Jan 18 2021 Read 3347 Times
Funding of £2.5 million is being invested in a COVID-19 drug screening and resistance hub at the MRC-University of Glasgow Centre for Virus Research (CVR) in partnership with medical research charity LifeArc, which has donated £2 million and the MRC which has provided additional funding.
The ground-breaking project, CRUSH (COVID-19 Drug-Screening and Resistance Hub), dedicated to supporting global scientific effort and accelerating vital COVID-19 antiviral innovation drug translation, will be delivered by the partners and the University of Dundee Drug Discovery Unit.
Professor Massimo Palmarini, Director of the CVR, said: “The establishment of CRUSH is an exciting development for the CVR and we are delighted to be partnering with LifeArc on this initiative.